{"id":"NCT00078819","sponsor":"Amgen","briefTitle":"Etanercept (Enbrel®) in Psoriasis - Pediatrics","officialTitle":"Placebo-controlled Multicenter Study With Etanercept to Determine Safety and Efficacy in Pediatric Subjects With Plaque Psoriasis (PEDS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09-08","primaryCompletion":"2006-02-01","completion":"2007-06-01","firstPosted":"2004-03-09","resultsPosted":"2019-07-29","lastUpdate":"2019-07-29"},"enrollment":211,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Etanercept","otherNames":["Enbrel®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Etanercept","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and efficacy of etanercept (Enbrel®) in children with Psoriasis.","primaryOutcome":{"measure":"Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12","timeFrame":"Baseline and week 12","effectByArm":[{"arm":"Placebo","deltaMin":11,"sd":null},{"arm":"Etanercept","deltaMin":57,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29106714","20185386","20619489","20633781","18199863","20833444","21960290"],"seeAlso":["http://www.amgentrials.com","http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf","http://download.veritasmedicine.com/REGFILES/amgen/08D_FDAMA_113_Posting_Summary_916_ENBREL_20030211.pdf","http://www.enbrel.com/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Upper Respiratory Tract Infection","Headache","Nasopharyngitis","Pharyngolaryngeal Pain","Influenza"]}}